Effects of Folic Acid Before and After Vitamin B12 on Plasma Homocysteine Concentrations in Hemodialysis Patients with Known MTHFR Genotypes

Pastore, Anna; Angelis, Sandro De; Casciani, Stefania; Ruggia, R; Giovamberardino, Gianna Di; Noce, Annalisa; Splendiani, G; Cortese, Claudio; Federici, Giorgio; Dessı̀, Mariarita

doi:10.1373/clinchem.2005.056119

Cited by 29 publications

(17 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a double-blind randomized controlled trial on patients with advanced CKD or ESRD, Jamison and collaborators showed that treatment with high doses of B-vitamins did not improve survival or reduce the incidence of vascular disease [6]. In our previous study, we demonstrated the importance of folate therapy and the secondary contribution of vitamin B 12 in lowering tHcy in hemodialysis (HD) patients, and that this decrease correlated to the MTHFR genotype [7]. Furthermore, we reported that supplementation with both vitamin B 12 and folate is useful only in HD patients with the wild-type genotype [7].…”

Section: Introductionmentioning

confidence: 94%

“…In our previous study, we demonstrated the importance of folate therapy and the secondary contribution of vitamin B 12 in lowering tHcy in hemodialysis (HD) patients, and that this decrease correlated to the MTHFR genotype [7]. Furthermore, we reported that supplementation with both vitamin B 12 and folate is useful only in HD patients with the wild-type genotype [7]. Most recently, Rafeq et al [8] reported that even if hHcy is associated with diastolic dysfunction in patients with CKD, B-vitamin therapy did not improve heart failure (HF) outcomes despite lowering of plasma Hcy levels.…”

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Homocysteine, cysteine, folate and vitamin B12 status in type 2 diabetic patients with chronic kidney disease

Pastore

Noce²,

Giovamberardino

et al. 2014

J Nephrol

Self Cite

View full text Add to dashboard Cite

Hyperhomocysteinemia (hHcy) is a risk\ud factor in the progression of chronic kidney disease (CKD).\ud In type 2 diabetes (T2D), hHcy is strongly associated with\ud increased risk of cardiovascular disease. Vitamin B12 and\ud folic acid supplementation have been reported to lower\ud homocysteine (tHcy) levels, but no data on plasma tHcy,\ud cysteine (Cys), folate and vitamin B12 levels in T2D-CKD\ud patients are reported.\ud Procedures tHcy and Cys levels were analyzed in 178\ud T2D-CKD patients by high performance liquid chromatography\ud (HPLC) with fluorescence detection. In addition,\ud we determined folate and vitamin B12 levels using a\ud chemiluminescence method.\ud Results tHcy and Cys levels were increased in T2D\ud patients, and this rise positively correlated with the CKD\ud stage (P\0.001). Folate levels were comparable to controls\ud at various CKD stages, whereas vitamin B12 levels\ud were lower, except at stage IV. We did not find any\ud correlation between B-vitamins and levels of tHcy and Cys,\ud regardless of the CKD stage.\ud Conclusions This is the first study reporting tHcy, Cys\ud and B-vitamins status in T2D-CKD patients. Although\ud limited to our cohort of 178 patients, our findings could be\ud helpful in clarifying the conflicting literature regarding\ud B-vitamins supplementation. Further studies are necessary\ud before any Hcy-lowering therapy can be safely established\ud in T2D-CKD subjects

show abstract

Section: Introductionmentioning

confidence: 94%

Section: Introductionmentioning

confidence: 98%

Homocysteine, cysteine, folate and vitamin B12 status in type 2 diabetic patients with chronic kidney disease

Pastore

Noce²,

Giovamberardino

et al. 2014

J Nephrol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Plasma total Hcy was assayed by a fully automated HPLC method using reversed-phase separation and fluorescence detection as reported previously (Pastore et al 2006). Creatinine was determined by an automated method using the Modular P800 (Roche) apparatus.…”

Section: Analytical Proceduresmentioning

confidence: 99%

Erythrocyte glutathione transferase: a potential new biomarker in chronic kidney diseases which correlates with plasma homocysteine

et al. 2011

Self Cite

View full text Add to dashboard Cite

The erythrocyte glutathione S-transferase (e-GST) is a member of a superfamily of inducible enzymes involved in cell detoxification that shows an increased expression in chronic kidney disease (CKD) patients. We propose a new automated analysis procedure for e-GST activity that has been validated in 72 CKD patients and 62 maintenance hemodialysis patients (MHD). Regression analysis was carried out to assess association between e-GST activity data, main clinical variables, and plasma homocysteine (Hcy), a modified sulfur amino acid known as potential risk factor for cardiovascular disease that is increased above normal levels in more than 90% of the uremic patients. An increased e-GST activity was confirmed in MHD patients (N=62; 10.2±0.4 U/gHb) compared with healthy subjects (N=80; 5.8±0.4 U/gHb), and as an original finding, a significant increase of e-GST activity was observed in pre-dialysis CKD patients with a positive correlation with disease severity weighted according to the four stages of "Kidney Disease Outcomes Quality Initiative" classification (7.4±0.5, 8±1, 9.5±0.6, 12±1 U/gHb, respectively). No correlation was found between e-GST activity and hemoglobin, transferrin, blood iron and the markers of systemic inflammation and renal function such as alpha-1 acid glycoprotein and high-sensitive C-Reactive Protein, beta-2 microglobulin and the index of malnutrition-inflammation PINI, while a significant correlation was observed for the first time between plasma Hcy and e-GST activity (r2=0.64, P<0.0001) in MHD patients. Hcy, however, was not identified as an inhibitor of e-GST enzyme. The results in this study suggest the potential for automated e-GST analysis as a valuable tool to further explore phase II-related uremic toxicity in CKD and MHD patients.

show abstract

“…Treatment with vitamin B12 and folic acid, but not vitamin B12 alone, appears to be effective for lowering the total plasma homocysteine concentration in hemodialysis patients who have either normal vitamin B12 concentrations or a deficiency (Pastore et al, 2006). In addition, adding vitamin B12 to a folate supplement can further enhance the reduction of plasma homocysteine, as compared to treatment with folate alone (Stopper et al, 2008).…”

Section: Vitamin B12mentioning

confidence: 99%

Micronutrient Metabolism in Hemodialysis Patients

Guo¹,

Wang²,

Chen³

2011

Hemodialysis - Different Aspects

View full text Add to dashboard Cite

Effects of Folic Acid Before and After Vitamin B12 on Plasma Homocysteine Concentrations in Hemodialysis Patients with Known MTHFR Genotypes

Cited by 29 publications

References 11 publications

Homocysteine, cysteine, folate and vitamin B12 status in type 2 diabetic patients with chronic kidney disease

Homocysteine, cysteine, folate and vitamin B12 status in type 2 diabetic patients with chronic kidney disease

Erythrocyte glutathione transferase: a potential new biomarker in chronic kidney diseases which correlates with plasma homocysteine

Micronutrient Metabolism in Hemodialysis Patients

Contact Info

Product

Resources

About